BibTex format
@article{Yang:2026:10.1111/all.70436,
author = {Yang, F and Seo, S and Hasegawa, T and Bloom, CI and Zounemat-Kermani, N and Bhavsar, PK and Raby, K and Adcock, IM and Won, S and Kim, T-B and Chung, KF and Unbiased, Biomarkers for the Prediction of Respiratory Disease Outcomes UBIOPRED Consortium},
doi = {10.1111/all.70436},
journal = {Allergy},
title = {Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.},
url = {http://dx.doi.org/10.1111/all.70436},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: Longer asthma duration predicts non-remission in Type-2 (T2) biologic-treated severe asthma, but underlying mechanisms remain unclear. We investigated associations between asthma duration and inflammatory biomarkers that may explain differential biologic response. METHODS: We analysed cross-sectional data from adults with severe asthma in U-BIOPRED. Asthma duration was defined as years from diagnosis to study entry. T2 and non-T2 biomarkers were measured in blood and sputum. Identical assays were performed in PRISM, a validation cohort of biologic-initiators. Multivariable regression models adjusted for age, sex, ethnicity, BMI, smoking and oral corticosteroid dose. Associations between duration-related biomarkers and 12-month biologic remission were explored in PRISM. RESULTS: In U-BIOPRED (n = 411), median asthma duration was 23 years (IQR 12-38). Longer duration was associated with higher non-T2 biomarkers including sputum CXCL9 (β = 0.024, 95% CI 0.011-0.038), sputum IL-6 (β = 0.024, 95% CI 0.011-0.037) and sputum neutrophils (β = 0.009, 95% CI 0.001-0.017), but lower T2 biomarkers including plasma periostin (β = -0.006, 95% CI -0.009 to -0.003), eosinophils (blood: β = -0.002, 95% CI -0.003 to -0.001; sputum: β = -0.023, 95% CI -0.035 to -0.011), sputum EDN (β = -0.032, 95% CI -0.049 to -0.014) and FeNO (β = -0.006, 95% CI -0.010 to -0.001). PRISM (n = 474) confirmed these associations. Higher sputum CXCL9 was associated with reduced remission in anti-IL-4Rα-treated patients with asthma duration ≥ 20 years (β = -1.73, 95% CI -3.180 to -0.276). CONCLUSION: Longer asthma duration was associated with elevated airway non-T2 inflammation and reduced systemic and airway T2 inflammation. This highlights the importance of airway bio
AU - Yang,F
AU - Seo,S
AU - Hasegawa,T
AU - Bloom,CI
AU - Zounemat-Kermani,N
AU - Bhavsar,PK
AU - Raby,K
AU - Adcock,IM
AU - Won,S
AU - Kim,T-B
AU - Chung,KF
AU - Unbiased,Biomarkers for the Prediction of Respiratory Disease Outcomes UBIOPRED Consortium
DO - 10.1111/all.70436
PY - 2026///
TI - Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.
T2 - Allergy
UR - http://dx.doi.org/10.1111/all.70436
UR - https://www.ncbi.nlm.nih.gov/pubmed/42423296
ER -